RVMD / Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel more_horizontal

Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancreatic cancer. High numbers of unconfirmed respons more_horizontal

Revolution Medicines is a clinical-stage biotech. The company has nearly a million in cash to develop its deep pipeline. more_horizontal

Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The more_horizontal

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Direc more_horizontal

Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but a more_horizontal

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing target more_horizontal

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director o more_horizontal